Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Inactivated influenza vaccine (split virion)
Inactivated influenza vaccine · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Inactivated influenza vaccine (split virion) | BIOLOGICAL | 0.5 mL, Intramuscular |
Inclusion Criteria: * Aged at least 18 years on the day of inclusion * Informed consent form signed * Able to attend all scheduled visits and to comply with all trial procedures * For a woman, inability to bear a child or negative urine pregnancy test at Visit 1 * For a woman of child-bearing poten...
Top 8 of 11 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 3 | PHASE3 | mRNA Seasonal Flu vaccine, Flu/COVID-19 mRNA combination vaccine |
| Sinovac Biotech Ltd. | SVA | 1 | PHASE3 | Quadrivalent influenza vaccine (split virion), inactivated |
| Moderna, Inc. | MRNA | 2 | PHASE3 | mRNA-1018-H5, mRNA-1010, Fluarix Trivalent |
| Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | CDTX | 1 | PHASE3 | CD388 |
| Traws Pharma, Inc. | TRAW | 2 | PHASE2 | TRX-100 |
| Sanofi SA Sponsored ADR | SNY | 4 | PHASE1 | H5N8 pandemic influenza vaccine (adjuvanted) |
| Hoffmann-La Roche | RHHBY | 2 | PHASE3 | Baloxavir Marboxil |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD4117, AZD5315 |
Inactivated influenza vaccine is used to prevent influenza, a respiratory illness caused by influenza viruses. It is also known as inactivated influenza vaccine (split virion). The vaccine is designed to stimulate an immune response against influenza and related Orthomyxoviridae infections. It is administered to healthy volunteers and adults, as studied in clinical trials.
Inactivated influenza vaccine is developed by Sanofi, which trades under the ticker symbol SNY. Sanofi is a global pharmaceutical company that produces vaccines and other therapeutic products. The company conducted a Phase 2 trial of this vaccine in Switzerland and the United Kingdom.
Inactivated influenza vaccine is in Phase 2 clinical development. A Phase 2 trial has been completed, but the vaccine is not yet approved. It remains an investigational product for the prevention of influenza.
Inactivated influenza vaccine has been studied in one completed Phase 2 clinical trial, NCT00343681. The trial was titled "A Study of the Immunogenicity and Safety of the 2006-2007 Influenza Vaccine" and enrolled 120 participants aged 18 years and older. It took place in Switzerland and the United Kingdom and included healthy volunteers.
Yes, inactivated influenza vaccine is also known as inactivated influenza vaccine (split virion). The two names refer to the same vaccine product developed by Sanofi. The split virion designation describes the vaccine's composition, which contains disrupted influenza virus particles.